Help Shape Group Hotel Rates for Biotech Week Boston & RESI 2027: Take the 30-Second Lodging Survey

By Caitlin Dolegowski, Program Director, LSN

As the life science calendar ramps up, planning is already actively underway for next year’s Biotech Week Boston and the concurrent RESI Boston partnering conference.

Every autumn, thousands of early-stage biopharma and medtech founders, active investors, corporate pharmaceutical business development executives, and service providers descend upon Massachusetts. While the week delivers immense value through high-stakes dealmaking, one persistent hurdle facing attendees year after year is Boston’s notoriously tight lodging market.

To help our community manage travel overhead and secure prime accommodations, the Life Science Nation (LSN) and RESI conference operations team is currently actively negotiating discounted room blocks with premier 4-star properties across the Back Bay and Copley area – right in the central corridor of the week’s key activities.

To ensure we secure the deepest volume discounts and reserve the appropriate room inventory for your team, we need your direct input.

Why Lodging in Boston Requires Advance Coordination

Hotel pricing across central Boston spikes significantly during Biotech Week, driven by global industry demand. Individual reservations made late in the cycle often face exorbitant rack rates or require staying far outside the primary event clusters.

By consolidating the collective purchasing power of our attending founders, investors, and regional tech hub delegations, LSN negotiates dedicated group blocks designed to:

  • Cap Peak-Rate Volatility: Lock in pre-negotiated, below-market room rates during one of the city’s highest-occupancy weeks.
  • Keep Teams Centrally Located: Anchor attendees within walking distance of The Westin Copley Place and key partnering venues, eliminating unnecessary commute friction across town.
  • Guarantee Sufficient Inventory: Provide your executive team, board members, and business development leads with confirmed space before room blocks sell out.

Take the 30-Second Lodging Survey

Our room block allocations and target rate negotiations directly depend on the aggregate requirements of the companies planning to participate.

Whether your organization plans to send a single executive or an entire delegation, please take 30 seconds to share your general lodging preferences:

Take the 30-Second Biotech Week Boston Hotel Survey

(The survey is completely anonymous, requires no login, and takes under a minute to complete.)

What Happens Next

Your feedback on target price points, stay duration, and room count will directly equip our negotiation team as we finalize contracts with Back Bay hotel partners in the coming weeks. Once group blocks are locked in, confirmed booking links and preferential access will be shared with registered delegates and newsletter subscribers.

Thank you for helping us make Biotech Week Boston both highly productive and cost-effective for the early-stage life science community.

For any specific questions regarding group delegations, corporate sponsorships, or partnering registration, please reach out to the RESI team at resi@lifesciencenation.com.

Take the 30-Second Biotech Week Boston Hotel Survey

Hot Investor Mandate: US-Based VC Firm Invests $250K–$3M in Seed and Series A HealthTech, MedTech, and Biotechnology Companies

The firm is a U.S.-based venture capital investor managing multiple investment vehicles with complementary investment strategies. Through its healthcare-focused fund, the firm primarily invests in Seed and Series A companies, making initial equity investments ranging from $250K–$3M. The firm prefers to lead financing rounds and requires board representation, although co-investments may also be considered. Through a separate diversified investment vehicle, the firm makes smaller investments of approximately $100K–$250K across a broader range of industries and development stages, including later-stage and Pre-IPO opportunities. The firm primarily invests in the United States and may consider international companies that have completed applicable regulatory processes.

The firm’s healthcare investment strategy focuses on healthtech, medical technology, and biotechnology, with particular interest in in vitro diagnostics, software-based digital health solutions, gene editing, and cell therapies. Within medical devices and diagnostics, the firm considers Class I and 510(k) regulatory pathways but generally excludes devices requiring Premarket Approval (PMA). The firm prioritizes revenue-generating companies demonstrating commercial scalability, repeat customers, and recurring business opportunities. The firm’s diversified investment strategy also considers companies across artificial intelligence, technology, aerospace, defense, and other high-growth industries.

From a company and management team perspective, the firm takes a founder-friendly approach and does not impose strict management team requirements. For healthcare investments, the firm emphasizes commercial traction, scalable business models, and demonstrated customer demand. The firm generally prefers to lead healthcare financing rounds and requires a board seat to maintain active governance involvement. Investment requirements and governance expectations under the firm’s diversified investment strategy may vary depending on the opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Global Therapeutics VC Invests Up to $5-6M in Seed to Series B Genetic Medicine and Advanced Therapeutic Modalities

The firm is a Europe-based venture capital investor focused exclusively on therapeutics, with an investment team spanning Europe, North America, and the Middle East. The firm typically makes several new investments annually and invests from Seed through Series B, with commitments of up to approximately $5M–$6M per company. The firm is flexible regarding financing structures and considers traditional equity investments, SAFEs, and convertible notes. The firm can co-lead financing rounds or participate in investment syndicates. The firm invests globally, with significant investment activity in North America.

The firm invests exclusively in therapeutics and has a particular preference for advanced therapeutic modalities, especially genetic medicines. The firm is broadly indication-agnostic and considers a wide range of therapeutic approaches on a case-by-case basis. The firm focuses on preclinical-stage companies developing differentiated therapeutic technologies with strong scientific foundations and the potential to address meaningful unmet medical needs. While advanced modalities represent a priority, the firm remains open to other therapeutic technologies demonstrating compelling scientific and commercial potential.

From a company and management team perspective, the firm does not impose specific requirements regarding leadership composition or prior entrepreneurial experience. The firm seeks companies developing differentiated therapeutic programs with credible scientific rationale and opportunities for significant value creation. The firm is comfortable participating alongside other investors and may take a co-lead role depending on the financing opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Healthcare-Focused Impact VC Targets Series A Oncology Therapeutics and Cardiovascular Medical Devices

The firm is an impact-oriented venture capital investor focused on advancing innovative healthcare technologies with significant clinical and commercial potential. The firm is developing a dedicated healthcare investment fund targeting approximately $150M in commitments and primarily invests at the Series A stage. The firm deploys equity capital to support companies approaching important clinical, regulatory, or commercial milestones. The firm primarily targets opportunities in the United States, with selective interest in Europe and Israel.

The firm focuses on oncology therapeutics, cardiovascular medical devices, and other differentiated healthcare innovations. Within oncology, the firm is modality-agnostic and evaluates novel therapeutic approaches with strong scientific rationale and clearly defined development pathways. The firm generally prefers therapeutic programs approaching IND clearance or entering early clinical development. Within medical devices, the firm has a particular interest in cardiovascular technologies and prioritizes FDA-regulated products requiring Premarket Approval (PMA), while remaining open to select 510(k) devices. Medical device companies are generally expected to have a functional prototype. The firm may also consider opportunities outside its core sectors when technologies demonstrate exceptional innovation and substantial growth potential.

From a company and management team perspective, the firm seeks experienced leadership teams capable of executing clinical development, regulatory, and commercialization strategies. The firm prioritizes strong scientific foundations, credible development plans, and clear pathways toward meaningful patient impact. The firm takes an engaged investment approach and supports portfolio companies through strategic guidance, governance participation, and access to clinical, regulatory, and industry networks.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Global Life Sciences CVC Invests in Series A and B Therapeutics, Diagnostics, and Drug Discovery Technologies

The firm is the corporate venture capital arm of a diversified global company with established businesses across healthcare, advanced materials, and imaging technologies. The firm manages a dedicated life sciences investment fund focused on innovative technologies with strong commercial and strategic potential. Initial investments typically begin in the several-hundred-thousand-dollar range, with capacity for follow-on investments. The firm primarily targets Series A and Series B companies and generally participates as a co-investor. The firm invests globally, with opportunities evaluated based on their alignment with the parent company’s healthcare and life sciences businesses.

The firm invests across therapeutics, diagnostics, medical technologies, and drug discovery enabling technologies. Areas of particular interest include regenerative medicine, cell therapies, small molecules, and innovative R&D platforms. Within diagnostics and medical technology, the firm evaluates medical imaging systems, endoscopy, ultrasound, in vitro diagnostics, veterinary diagnostics, and AI-enabled diagnostic technologies. The firm is broadly opportunistic across therapeutic indications and prioritizes technologies that complement its existing capabilities in healthcare, biotechnology, and life sciences. The firm is comfortable evaluating early-stage technologies, including preclinical therapeutic programs and products still under development.

From a company and management team perspective, the firm does not impose specific requirements regarding team composition or organizational maturity. The firm seeks differentiated technologies with strong growth potential and opportunities for strategic collaboration. Beyond equity investments, the firm may explore research collaborations, licensing, and other strategic partnerships that leverage its parent company’s research, manufacturing, and commercialization capabilities.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

From Asset to Licensing Campaign: Finding the Right Partners, Benchmarks, and Deal Terms

In this interview, Patrik Frei explains how biotech CEOs can use Biotechgate to identify potential licensing partners, assess competing programs, and benchmark relevant transactions. He also discusses how Venture Valuation can help turn that research into a licensing strategy and potential deal terms. 

Patrik Frei
Founder and CEO at Venture Valuation AG
Caitlin Dolegowski
Program Director, LSN

Caitlin Dolegowski (CD): Let’s start with the asset. If I’m the CEO and want to license it to pharma, what do you need to know before you start looking for potential partners? 

Patrik Frei (PF): Who the ideal partner would be. It is not always big pharma. Mid-size and specialty companies are often the better fit.

  • When the right time to out-license is. That moment can differ from partner to partner, depending on the data each one needs to see before engaging.
  • How much time you have. Building the relationship takes months or years, not weeks. An out-licensing deal cannot be expected within one or two months.
  • What makes your asset different. You need a clear, evidence-based answer on why it is better than the programs already on a partner’s desk.

CD: Who should I approach? Show us how you would use Biotechgate to find pharma companies with a plausible fit based on their pipelines, therapeutic interests, geography, and previous licensing activity. Does the platform generate an initial target list from my asset description, or do I construct it through searches and filters? 

PF: In Biotechgate, you can see what pharma companies are actively looking to in-license. This is based on what they communicate at conferences, in presentations, and on their websites. It is classified by our analysts rather than guessed by an algorithm.

You add the stage, indication and, if relevant, the geography for out-licensing, and you get a target list of potential partners actively looking for that type of program. You build the list yourself through searches and filters, which keeps you in control of the criteria—and it takes minutes, not weeks. You can also set up an alert that tells you as soon as a new potential partner appears. And you can enter your search criteria in natural language using our AI-based workflow, which lets you run complex queries in plain words.

CD: How much of the market have we found? For this example, how many companies appear initially and how many remain after you assess fit? What portion of the credible global partner universe would you expect Biotechgate to capture, and where might important gaps remain? 

PF: As we work with over 30 local partners around the world—from Ausbiotech, BioTaiwan, HollandBIO, UKBio, Maryland, BioFlorida to Ohio Life Sciences and many more—we capture a substantial share of the credible global partner universe. In an example like this one, a search typically starts with several hundred companies and narrows to a shortlist of 20 to 40 once stage, indication, and in-licensing intent are applied. The key is that our data are structured. This is not a general AI or web search. The list only includes companies that our analysts have classified as actively seeking assets, or that have declared this themselves.

We also have a Chinese-speaking analyst covering that increasingly important market. If I had to point to where our coverage is relatively thinner, I would say Africa, South America and, to a lesser extent, Japan.

CD: Can I reach the right people? What names, responsibilities, email addresses, and phone numbers are available for those companies? Can I download the target list and contacts into my CRM? How do I verify that a person is current and handles licensing opportunities like mine? 

PF: We have invested a great deal of effort in collecting the relevant contacts in each company: name, role, and responsibility. For big pharma, we identify the business development person responsible for the specific indication or stage, and provide email and LinkedIn details. Our analysts review and update these records on an ongoing basis, and LinkedIn gives you a second, independent check that a person is still in the role.

All information can be searched, refined, and downloaded in Excel format. From there, it can be imported into any CRM or used in whatever format suits your workflow. We also provide an API that gives you direct access to the data.

Within a company, many people are usually involved. The key is to find a champion who is genuinely interested in your asset. That person will bring the right colleagues on board. Biotechgate gives you the best chance of identifying that entry point. It is just as important to meet people face to face at conferences such as RESI. Biotechgate provides the verified intelligence to identify that exact champion, and pairing that targeted research with direct, face-to-face partnering at focused conferences like RESI creates the highest-converting path from cold lead to executed term sheet.

CD: What is my global competition? How would you find similar assets and examine their owners, stage, clinical activity, and licensing status? What makes another program a genuine alternative for a potential pharma partner? 

PF: Biotechgate has a very intuitive interface. All data are attached to a company, and you can search by company, asset, financing round, licensing deal, clinical trial, and more. To identify similar assets, the best route is to search by asset and select the stage, indication, and sub-indication. This gives you a list of similar assets, their companies, the management of those companies, and their investors.

Another key differentiator is how Biotechgate combines curated, structured data with AI. Many so-called “AI companies” rely primarily on unstructured documents and let a language model extract answers from them. That works well for summarizing text, but it struggles with questions that require completeness and precision, such as, “Which oncology licensing deals above USD 100 million were signed in Europe in the last three years?” Answering that reliably requires data that has been verified, standardized, and linked. At Biotechgate, structured data is the source of truth, and AI is the layer that makes it fast and intuitive to explore.

Pharma is looking for first-in-class or best-in-class. A competing program becomes a genuine alternative when it addresses the same indication with a comparable or better profile and sits at a similar or more advanced stage. That is why every biotech has to understand its competitive landscape before approaching partners. It is also crucial to understand what licensing deals a potential partner has already done and on what terms.

CD: Where does my asset stand? Can Biotechgate show the evidence needed to compare my program with those alternatives? Does it generate a rank or assessment, or must the CEO and advisers judge relative position from the data? 

PF: Biotechgate provides the evidence—stage, clinical trials, indication and sub-indication, primary market, originator, administration mode, and molecule type—but it does not score or rank the result. We deliberately leave the judgment to the CEO and their advisers. If an independent view is needed, Venture Valuation can assess the relative position of the asset. A score would hide the assumptions behind it. Partners will challenge your reasoning, not your rating, so the underlying evidence has to hold up.

CD: What happened to similar assets? How would you find relevant pharma licensing agreements and venture financings? Which terms and financial details are available, which are usually undisclosed, and how do you avoid treating an announced deal’s maximum value as cash received? 

PF: Starting from the asset, you can see immediately which licensing deals and agreements have been signed for comparable programs. For some deals, you can even access the actual contract that was signed as a PDF download, and you can trace the financing rounds and investors that have backed companies with equivalent assets.

Biotechgate has over 40,000 licensing deals, over 10,000 deal values, and over 1,700 actual licensing agreements. Additional information includes upfront payments, regulatory and commercial milestones, equity investments, and royalties. Royalty rates and the detailed milestone schedule are the terms most often left undisclosed.

Because we separate the individual components of a deal—in particular, the upfront from the milestones—Biotechgate shows the difference between the headline deal value and the cash actually received at signing. That stops anyone from mistaking an announced biodollar total for money in the bank.

CD: What might my asset and a deal be worth? What does Venture Valuation’s independent analysis add to the database research? How would you test development risk, market assumptions, and different combinations of upfront cash, milestones, and royalties—including the effect of reaching the next development milestone before licensing? 

PF: Biotechgate gives you solid benchmarks for comparable transactions. On top of that, Venture Valuation provides an individual calculation of potential licensing deal terms. Based on the specific asset, time to market, development risk, market size, and uniqueness, we model front-loaded or back-loaded structures. We can also show what the same asset would be worth after the next development milestone, so you can decide whether to license now or wait.

Without that work, it is hard to know how to set upfront payments, milestones, and royalties once negotiations start. Pharma typically wants to know a biotech’s ballpark figures early on, so you have to be prepared.

CD: What do I take into a licensing campaign? At the end of our example, describe the target list, contact information, competitive landscape, transaction comparisons, and valuation analysis the CEO could have in hand. Which pieces are available through a Biotechgate subscription, which require your team’s services, and how should a CEO get started? 

PF: A biotech CEO ends up with the full package: a qualified target list, named contacts with email and LinkedIn details, the competitive landscape, and comparable transactions—all available through a Biotechgate subscription—plus a tailor-made asset valuation with concrete deal term proposals, which is where our Venture Valuation team comes in.

The best way to start is a short call with us and a trial of the database, so you can run your own asset through it. Biotechgate is the deal-making tool every CEO needs.

The practical test is to bring a real asset to Patrik’s team and see what the research produces: a potential partner universe, available contacts, competing programs, and relevant transactions. From there, a CEO can decide whether an independent valuation would help shape the licensing discussion. That work can provide the foundation for a global partnering campaign. Readers who want to explore what Biotechgate and Venture Valuation can deliver for their asset can contact Patrik’s team at https://www.biotechgate.com/.

Register for RESI JPM 2027

Investor Outreach Support at RESI JPM 2027

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

RESI JPM 2027 will take place January 11 and 12 at the San Francisco Marriott Marquis, with virtual partnering days on January 13, 18 and 19.

For early-stage life science companies, effective partnering starts with finding investors whose interests and requirements align with their company. RESI verifies and interviews investor attendees, then creates curated profiles for the partnering platform. With a standard RESI registration, companies can search investor profiles by investor type, name, indications, phase of development, capital structure preference and investment stage preference.

Companies seeking more detail can choose the Premier Package or Premier PLUS. Each option adds support for a different stage of the outreach process.

Premier Package

The Premier Package costs $750 and gives companies additional investor information to guide self-managed outreach. In addition to the details available through standard RESI access, Premier profiles include direct investor contact information, sectors and subsectors of interest, and company and management team requirements.

This added information can help fundraising teams identify investors that better match their company and contact them directly.

Premier PLUS

Premier PLUS costs $2,500 and includes all Premier Package benefits, along with hands-on outreach support from the Life Science Nation team.

LSN helps identify relevant investors and strategic partners, prepares tailored messaging, manages communications and scheduling, and works to secure confirmed meetings before the conference. Premier PLUS is designed for companies that want support coordinating the outreach process while they focus on their fundraising campaign. Availability for Premier PLUS is limited.

Option 1: Premier Package
$750
Full Contact & Mandate Intelligence
Unlock direct investor contact details and detailed investment criteria to execute precise self-managed outreach:
• Direct Contact Info: Verified emails and direct phone numbers for decision makers.
• Granular Criteria: Sectors and subsectors of interest.
• Mandate Fit: Company & management team requirements.
• Complete investor profiles and preferences.
Option 2: Premier PLUS
$2,500
Full Turnkey Outreach Management
Hands-on support from the LSN team to run your investor partnering from start to finish:
• Target Identification: Sourcing relevant investors and strategic partners.
• Custom Messaging: Tailored, professional pitch copy for each contact.
• Active Management: Full communication and schedule coordination.
• Meeting Delivery: Confirmed meetings booked prior to arrival.

*Limited Spots: Dedicated 1-on-1 team capacity is strictly capped.
⏰ Deadline: Premier PLUS registration closes Monday, November 16!
(Includes all Premier Package benefits)

📊 Feature Comparison: RESI Standard vs. Premier Package

Features RESI Standard Premier Package
Investor Type ✓ ✓
Investor Name ✓ ✓
Indications ✓ ✓
Phase of Development ✓ ✓
Capital Structure Preference ✓ ✓
Investment Stage Preference ✓ ✓
Direct Investor Contact Info (Email, Phone) ✕ ✓
Sectors & Subsectors of Interest ✕ ✓
Company & Management Team Requirements ✕ ✓

Choosing the right option

Standard RESI access provides investor profiles with core information for searching and evaluating potential matches. The Premier Package adds contact details and more specific investment criteria for companies managing their own outreach. Premier PLUS adds LSN support for research, messaging, communication and meeting coordination.

How to add a Premier option

Companies registering for RESI JPM 2027 can select Premier or Premier PLUS as an add-on in the registration portal. Companies that have already registered can contact salescore@lifesciencenation.com to add an upgrade to their existing account.

Register for RESI JPM & Add Premier Partnering